A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Saved in:
| Title: | A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. |
|---|---|
| Authors: | Jimeno, A.1, Shirai, K.2, Choi, M.3, Laskin, J.4, Kochenderfer, M.5, Spira, A.6,7, Cline-Burkhardt, V.8, Winquist, E.9, Hausman, D.10, Walker, L.10, Cohen, R. B.11 |
| Source: | Annals of Oncology. Mar2015, Vol. 26 Issue 3, p556-561. 6p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
